We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.
- Authors
Milanović, Dušan; Braun, Friederike; Weber, Wolfgang; Grosu, Anca Ligia; Behe, Martin; Niedermann, Gabriele
- Abstract
One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of established tumor vessels and subsequent tumor hemorrhagic necrosis. Its selective antivascular effect is mediated by intratumoral induction of several cytokines including tumor necrosis factor-α (TNF-α), granulocyte-colony-stimulating factor (G-CSF), interleukin 6 (IL-6) and macrophage inflammatory protein 1α (MIP-1α). Preclinical studies have demonstrated that ASA404 acts synergistically with taxanes. In this study, we investigated if treatment of mice bearing U251 human glioblastoma xenografts with ASA404 and taxol may be synergistic. Therapy response was evaluated by measuring changes in tumor size and metabolic activity using 18F-FDG PET (Fluorodeoxyglucose - positron emision tomography) imaging.
- Publication
BMC cancer, 2012, Vol 12, p242
- ISSN
1471-2407
- Publication type
Journal Article
- DOI
10.1186/1471-2407-12-242